PT-141 + Kisspeptin
Sold as one compound for the brain and one for hormones. The evidence says both are working on the brain.
These are the two compounds with the most direct published human evidence for men's sexual function. The case for running both rests on them doing different jobs. In the one trial that measured whether kisspeptin affects desire, testosterone did not move at all.
Two mechanisms, on paper.
The reasoning is tidy. PT-141 acts on the desire circuits themselves. Kisspeptin sits at the top of the chain that produces testosterone, so it is meant to fix the background rather than the moment.
Two different systems, so the effects should add. That is the argument vendors make and it is the reason the pair gets bought together.
These are also the right two compounds to be asking about. One review names PT-141 and kisspeptin as the pair with the most direct published human evidence for men's sexual function, which puts them ahead of everything else in the category.[1]
Nobody sells them premixed. Both are bought as separate vials, which at least means the balance is yours to set.
Four benefits, and how well each one holds up.
The third row is the one that matters here, because the whole case for combining these two rests on it.
Three questions, answered before anything else.
Kisspeptin worked, and testosterone stayed flat.
Kisspeptin's strongest evidence for sexual function is a randomised, placebo-controlled crossover trial in men with hypoactive sexual desire disorder, published in JAMA Network Open.[2]
It found real effects. Kisspeptin substantially modulated sexual brain processing. Penile response to sexual stimuli rose by up to 56 percent more than on placebo. Behavioural measures of desire improved, including how happy men felt about sex.[2]
Testosterone and cortisol did not change over the study period, which the authors note is consistent with previous work.[2]
That is the finding this page turns on. The reason to pair kisspeptin with PT-141 rather than with a second desire compound is that it is supposed to work through hormones. In the trial measuring desire, it did not.
Kisspeptin does raise luteinising hormone and testosterone in controlled infusion studies, and that is well established.[3] Those are different studies, measuring different things, in different populations.
So the two-pathway argument holds in principle and the evidence for the sexual effect points at one pathway for both compounds. That does not make the pairing pointless. It does mean the reason usually given for it is weaker than it sounds.
Priming, rather than treatment.
The American Urological Association published a clinician-facing review of peptides in sexual medicine in April 2026, which is a more useful source than anything a vendor writes.[3]
On PT-141 it is positive. Phase 2 trials in men showed erection initiation without visual sexual stimulation, which supports a central mechanism, and the review calls PT-141 the compound with the strongest clinical evidence in the category.[3]
On kisspeptin it is more careful. Clinical studies have not demonstrated sustained improvements in erectile function or long-term libido enhancement. The review describes kisspeptin as neuroendocrine and motivational priming rather than a direct sexual performance therapy.[3]
It also describes the whole category as promising and largely investigational, which is a fair summary of where both compounds sit.[3]
A kisspeptin analog failed its primary endpoint.
Takeda ran a Phase 2a study of TAK-448, a kisspeptin analog, in middle-aged and older men with low testosterone. Randomised, single-blind, placebo-controlled.[4]
The trial was terminated. The registry records the reason as a sponsor decision because the study did not meet its primary endpoint.[4]
That is a different molecule and it does not settle anything about kisspeptin-10, the fragment sold as a research peptide. It is the closest anyone came to testing this approach for low testosterone at pharmaceutical scale, and the answer was no.
Kisspeptin itself has been given to humans widely in research settings: healthy men and women, postmenopausal women, men with low testosterone and type 2 diabetes, and patients with a specific hormone deficiency.[5] Those are mechanism studies rather than treatment trials.
Vendor copy on this stack gets a basic fact wrong.
One site selling the pair describes them as enhancing sexual desire and performance by increasing blood flow and sensitivity.[6]
PT-141 does not work on blood flow. Acting centrally rather than on the vascular system is the entire reason it reaches people the erection drugs do not, and it is the first thing every clinical source says about it. A page selling a compound while describing it as the opposite of what it is should lower your confidence in the rest of that page.
To be fair to the same category, another vendor selling this stack states plainly that the combination has never been tested in human trials and that it therefore has no verified result.[7] That is more honest than most.
We note both because the sourcing on this pairing is almost entirely commercial. The underlying compounds have real trials. The stack does not.
Two vials, no premixed option.
Nobody sells this combination ready-mixed, unlike PT-141 with oxytocin, where one vendor charges nearly four times the separate cost for the convenience.
Bought separately the pair comes to $41.07 at the cheapest in-stock listings.[8] Kisspeptin is the cheaper half and has the wider spread, running from $19.00 to $449.00 across the listings we track.
Buying separately also lets you stop one and keep the other, which matters on a pairing where the two halves have quite different evidence behind them.
One approved compound, one investigational.
PT-141 is approved as Vyleesi for low desire in premenopausal women, and for nothing else anywhere. That approval and who it covers is set out here.
Kisspeptin has no approval in any country for any use. It is investigational, and self-administration for sexual enhancement is not supported by current evidence.[9]
Almost all kisspeptin sold is kisspeptin-10, the shortest active fragment.[10] The research literature uses several isoforms by several routes, so a vial and a study are not always the same compound given the same way.
One combination to avoid is documented. PT-141 should not be taken alongside melanotan II or any other melanocortin agonist, because the receptors overlap. Kisspeptin does not act on those receptors, so that warning does not apply to this pairing.
What people ask about this stack
Does stacking PT-141 and kisspeptin work better than either alone?
Nobody has tested it. No human trial has given the two together, which one vendor selling the stack states plainly on its own page. Both compounds have real separate evidence and that evidence does not transfer to the combination. The usual argument for pairing them is that they work through different systems, and the trial measuring kisspeptin's sexual effect found it acting on the brain rather than on hormones.
Does kisspeptin raise testosterone?
In controlled infusion studies it reliably raises luteinising hormone and testosterone, and that is well established. In the randomised trial that measured sexual outcomes in men with low desire, testosterone and cortisol did not change over the study period. Both findings are real. They come from different studies measuring different things, which is why the compound is described as hormonal in vendor copy and as central in the trial that tested desire.
What did the kisspeptin desire trial find?
A randomised, placebo-controlled crossover trial in men with hypoactive sexual desire disorder found kisspeptin substantially modulated sexual brain processing. Physical arousal response to sexual stimuli was up to 56 percent greater than on placebo, and behavioural measures of desire improved, including how happy the men felt about sex. The authors describe it as the first evidence of its kind.
Is kisspeptin a treatment for low testosterone?
No trial has established that. Takeda ran a Phase 2a study of TAK-448, a kisspeptin analog, in middle-aged and older men with low testosterone, and terminated it because it did not meet its primary endpoint. That is a different molecule from the kisspeptin-10 sold as a research peptide, and it is the closest anyone has come to testing the approach at pharmaceutical scale.
Which of the two has better evidence?
PT-141, and a clinician-facing review by the American Urological Association says so directly, calling it the compound with the strongest clinical evidence in the category. That review describes kisspeptin as neuroendocrine and motivational priming rather than a direct sexual performance therapy, noting that clinical studies have not shown sustained improvements in erectile function or long-term libido enhancement.
What does it cost?
The pair comes to $41.07 at the cheapest in-stock listings, with PT-141 at $22.07 and kisspeptin at $19.00. No premixed version exists, which is unusual in this category and works in the buyer's favour. Kisspeptin has the wider price spread, running from $19.00 to $449.00 across the listings we track. Compare against the other stacks.
What this page is built on
- 01Review of peptides studied for men's libido. Source for PT-141 and kisspeptin being the two compounds with the most direct published human evidence for men's sexual function, and for the two acting through distinct mechanisms.
- 02Effects of kisspeptin on sexual brain processing and penile tumescence in men with hypoactive sexual desire disorder: a randomized clinical trial. JAMA Network Open. Full text. Penile tumescence in response to sexual stimuli up to 56 percent more than placebo, mean difference 0.28 units, 95% CI 0.04 to 0.52, P = .02. Behavioural measures of desire improved. No changes in testosterone or cortisol were observed during the 75-minute study period.
- 03Peptides for sexual dysfunction: what clinicians should know. AUANews, American Urological Association, April 2026. Article. Source for PT-141 having the strongest clinical evidence in the category, for Phase 2 erectogenic effects including erection initiation without visual sexual stimulation, for kisspeptin reliably increasing luteinising hormone and testosterone in humans, and for clinical studies not demonstrating sustained improvements in erectile function or long-term libido enhancement from kisspeptin.
- 04A randomized, single-blind, placebo-controlled Phase 2a study to evaluate the stimulatory effects of TAK-448, a kisspeptin analog, administered intermittently in middle-aged and older men with low testosterone. Takeda. NCT02381288. Status terminated; registry records the reason as a sponsor decision because the study did not meet its primary endpoint.
- 05Protocol document summarising the worldwide record of kisspeptin administration in humans, covering healthy men and women, postmenopausal women, patients with low testosterone and type 2 diabetes, and patients with isolated hypogonadotropic hypogonadism, across single and multiple boluses by intravenous and subcutaneous routes. Protocol PDF.
- 06A vendor page selling this stack describing PT-141 and kisspeptin as enhancing sexual desire and performance by increasing blood flow and sensitivity. Recorded here because PT-141 acts centrally rather than on blood flow, which every clinical source states.
- 07The same vendor page stating that the combination has never been tested in human trials and that the stack therefore has no verified result.
- 08Peptide Decoding vendor pricing data, 18 September 2026. Lowest in-stock single-compound listings: PT-141 $22.07 across 70 listings, kisspeptin $19.00 across 54, with kisspeptin ranging to $449.00. No premixed listing combining the two.
- 09Guide to peptides for men's sexual health. Source for kisspeptin's FDA status being investigational, not approved for any sexual health indication, and for self-administration for sexual enhancement not being supported by current evidence.
- 10Source for kisspeptin-10 being the shortest active fragment and the isoform almost always sold as a research peptide, and for a study in 29 healthy men in which brain activity rose in regions tied to arousal and attraction during kisspeptin infusion.